Mathilde Renaud

Faculty member / Enseignant-chercheur / Enseignante-chercheuse

Université de Lorraine
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Background Tatton-Brown-Rahman syndrome (TBRS; OMIM 615879), also known as DNA methyltransferase 3 alpha ( DNMT3A )-overgrowth syndrome (DOS), was first described by Tatton-Brown in 2014. This syndrome is characterised by overgrowth, intellectual disability and distinctive facial features and is the consequence of germline loss-of-function variants in DNMT3A , which encodes a DNA methyltransferase involved in epigenetic regulation. Somatic variants of DNMT3A are frequently observed in haematological malignancies, including acute myeloid leukaemia (AML). To date, 100 individuals with TBRS with de novo germline variants have been described. We aimed to further characterise this disorder clinically and at the molecular level in a nationwide series of 24 French patients and to investigate the correlation between the severity of intellectual disability and the type of variant. Methods We collected genetic and medical information from 24 individuals with TBRS using a questionnaire released through the French National AnDDI-Rares Network. Results Here, we describe the first nationwide French cohort of 24 individuals with germline likely pathogenic/pathogenic variants in DNMT3A , including 17 novel variants. We confirmed that the main phenotypic features were intellectual disability (100% of individuals), distinctive facial features (96%) and overgrowth (87%). We highlighted novel clinical features, such as hypertrichosis, and further described the neurological features and EEG results. Conclusion This study of a nationwide cohort of individuals with TBRS confirms previously published data and provides additional information and clarifies clinical features to facilitate diagnosis and improve care. This study adds value to the growing body of knowledge on TBRS and broadens its clinical and molecular spectrum.

Year:

2024

Variants in RNU4-2 , encoding the small nuclear RNA (snRNA) U4, were recently identified as a major cause of neurodevelopmental disorders (ReNU syndrome). Here, we investigated de novo variants in 50 snRNAs in a French cohort of 23,649 individuals with rare disorders and collected data of additional patients through an international collaboration. Altogether, we identified 133 probands with pathogenic or likely pathogenic variants in RNU4-2 and 15 individuals with de novo and/or recurrent variants in constrained regions of RNU5B-1 , one of five genes encoding U5. These variants cluster in evolutionarily conserved regions of U4 and U5 essential for splicing. RNU4-2 variants affecting stem III are associated with milder phenotypes than those in the T-loop (quasi-pseudoknot). Phaseable variants associated with severe phenotypes occurred on the maternal allele. Individuals with RNU4-2 variants show specific defects in alternative 5’ splice site usage, correlating with variant location and clinical severity. Additionally, we report an episignature associated with severe ReNU syndrome. This study further highlights the importance of de novo variants in snRNAs and establishes RNU5B-1 as a new neurodevelopmental disorder gene.

Year:

2024

Collaborators (11)

Caroline Schluth-Bolard

University of Lyon

FRANCE
View details

Julien Van-Gils

Aix-Marseille University

FRANCE
View details

Julie Steffann

-

FRANCE
View details

Dominique Bonneau

Professor of Medical Genetics

Université d'Angers

FRANCE
View details

Elsa Leitão

Universitätsklinikum Essen Institut für Humangenetik

GERMANY
View details

Florence Petit

Université de Lille

FRANCE
View details

Patrick Edery

Professor

Université Claude Bernard Lyon 1

FRANCE
View details

Pierre Blanc

Head of the laboratory

Assistance Publique - Hôpitaux de Paris

FRANCE
View details

Gael Nicolas

PUPH

University of Rouen

FRANCE
View details

Annick Toutain

-

FRANCE
View details

Benoit Arveiler

Prof - Group leader

Bordeaux University Hospital

FRANCE
View details